KALARIS THERAPEUTICS, INC. Variable Lease, Cost
KALARIS THERAPEUTICS, INC. (KLRS) reported Variable Lease, Cost of $7.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. variable lease, cost for the quarter ending 2026-06-30 was $7.00K.
- KALARIS THERAPEUTICS, INC. variable lease, cost for the quarter ending 2026-03-31 was $8.00K.
- KALARIS THERAPEUTICS, INC. variable lease, cost for the quarter ending 2024-12-31 was $0.00.
- KALARIS THERAPEUTICS, INC. variable lease, cost for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- KALARIS THERAPEUTICS, INC. variable lease, cost for fiscal 2025 was $6.00K, a 94.00% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. variable lease, cost for fiscal 2024 was $100.00K, a 88.89% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. variable lease, cost for fiscal 2023 was $900.00K, a 75.68% decline from fiscal 2022.
- KALARIS THERAPEUTICS, INC. variable lease, cost for fiscal 2022 was $3.70M, a 74.48% decline from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.00K 10-Q · filed 2026-08-11 | $15.00K 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $6.00K 10-K · filed 2026-03-17 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | $0.00 derived: sum of 3 quarters · filed 2025-03-07 | $100.00K 10-K · filed 2025-03-07 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $100.00K 10-Q · filed 2024-11-12 | $100.00K derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | $100.00K 10-Q · filed 2024-08-09 | $100.00K derived: sum of 3 quarters · filed 2025-03-07 | $300.00K derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-13 | $100.00K derived: sum of 2 quarters · filed 2025-03-07 | $300.00K derived: sum of 3 quarters · filed 2025-03-07 | $800.00K derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $200.00K derived: sum of 2 quarters · filed 2025-03-07 | $700.00K derived: sum of 3 quarters · filed 2025-03-07 | $900.00K 10-K · filed 2025-03-07 |
| 2023-09-30 | $200.00K 10-Q · filed 2024-11-12 | $700.00K derived: sum of 2 quarters · filed 2024-11-12 | $900.00K 10-Q · filed 2024-11-12 | $900.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-09 | $600.00K 10-Q · filed 2024-08-09 | $700.00K derived: sum of 3 quarters · filed 2024-08-09 | $2.20M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-13 | $200.00K derived: sum of 2 quarters · filed 2024-05-13 | $1.70M derived: sum of 3 quarters · filed 2024-05-13 | $2.60M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $1.60M derived: sum of 2 quarters · filed 2024-03-15 | $2.50M derived: sum of 3 quarters · filed 2024-03-15 | $3.70M 10-K · filed 2024-03-15 |
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-02 | $2.40M derived: sum of 2 quarters · filed 2023-11-02 | $3.60M 10-Q · filed 2023-11-02 | $9.00M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $900.00K 10-Q · filed 2023-08-03 | $2.20M 10-Q · filed 2023-08-03 | $7.50M derived: sum of 3 quarters · filed 2023-08-03 | $12.80M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.20M 10-Q · filed 2023-05-04 | $6.60M derived: sum of 2 quarters · filed 2023-05-04 | $11.90M derived: sum of 3 quarters · filed 2023-05-04 | $14.10M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $10.70M derived: sum of 2 quarters · filed 2023-02-15 | $12.90M derived: sum of 3 quarters · filed 2023-02-15 | $14.50M 10-K · filed 2023-02-15 |
| 2021-09-30 | $5.30M 10-Q · filed 2022-11-03 | $7.50M derived: sum of 2 quarters · filed 2022-11-03 | $9.10M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $2.20M 10-Q · filed 2022-08-04 | $3.80M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $900.00K 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | $1.20M 10-Q · filed 2021-11-05 | $3.70M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |